Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Published:2014-03 Issue:3 Volume:25 Page:657-662
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Leibowitz-Amit R.,Templeton A.J.,Omlin A.,Pezaro C.,Atenafu E.G.,Keizman D.,Vera-Badillo F.,Seah J.-A.,Attard G.,Knox J.J.,Sridhar S.S.,Tannock I.F.,de Bono J.S.,Joshua A.M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/3/657/16699121/mdt581.pdf

Reference20 articles.

1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

5. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate;Société Internationale d’Urologie Journal;2024-08-20

2. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer;Cancers;2024-07-14

3. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance;Nature;2023-10-16

4. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells;Nature Cancer;2023-07-17

5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2;Frontiers in Immunology;2023-05-18